Cardiovascular drug therapy in the elderly: benefits and challenges. - Wikidata - awgldk - TriplyDB

Cardiovascular drug therapy in the elderly: benefits and challenges.

Cardiovascular drug therapy in the elderly: benefits and challenges.

http://www.wikidata.org/entity/Q37803337

about

Inequalities in care in patients with acute myocardial infarction Managing hypertension in the elderly: a common chronic disease with increasing age Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats.Modulation of circulating macrophage migration inhibitory factor in the elderly Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association.Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study Lipids, blood pressure, kidney - what was new in 2011?Relationship of Blood Pressure With Mortality and Cardiovascular Events Among Hypertensive Patients aged ≥ 60 years in Rural Areas of China: A Strobe-Compliant Study.The intersection between aging and cardiovascular disease.Treatment of systemic hypertension.Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.Prognostic value of cardiovascular disease status: the Leiden 85-plus study.Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study.Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy.Biochemical and molecular aspects of vascular adrenergic regulation of blood pressure in the elderly Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly.Initiation of statin therapy: are there age limits?Current approaches to the treatment of hypertension in older persons.Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly.Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?Acute coronary syndrome management in older adults: guidelines, temporal changes and challenges.Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life.Association of cardiovascular system medications with cognitive function and dementia in older adults living in nursing homes in Australia.Treatment of isolated systolic hypertension in the elderly.Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study.Strategies for Achieving Healthy Vascular Aging.Cardiac function and cognition in older community-dwelling cardiac patients.Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria.Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study Management of hypertensive crises in the elderly

P2860

Q26771112-D3414556-BEBF-4BF8-8C99-E4E75A98BF1F Q27011805-14338CB3-A3D3-47B5-B828-731F72BC5472 Q27026525-6671FE33-5FD5-42D8-8E49-CE5D211C3295 Q28655596-BBA40A80-1247-4992-86B2-804D930507E2 Q33587189-5A8BDC3A-7D5A-439B-B2BB-D9C79D15B2B1 Q33992798-34583BD5-4B19-4E85-8FC4-7B12FCB13821 Q34088554-F1D9FC59-3BB1-41CF-8C61-965F4D3106DD Q34224601-942FFDAF-55C2-44F4-80A8-BB5C7D76CB81 Q35622601-556D3CA2-EA24-4E19-95F9-C4534EA36674 Q35691396-88D386CB-6161-4FDF-8ECF-DDEDA41BAF64 Q35795103-A4223C6B-BD55-40D0-A07C-ACAB66129C00 Q36006533-F4E8305B-77EC-4D4A-8956-553F12501C22 Q36190285-81D881BC-19D5-4A7D-916F-4937F89725AF Q36459987-5C7035AC-F029-41FA-BF7E-1104FDEA0C82 Q36993441-57C99E0F-FA2F-4F51-B99E-D85AB005DB61 Q37036369-65C5E5DA-0B10-4C79-8F9D-92CDFDB222A0 Q37671457-AF1CE119-14F0-4A3A-8228-0B7DF8641F91 Q37715489-2948FD68-95C2-490E-A3B7-A6E79D5B2A7B Q37941005-17B7F1BB-9698-4B70-9A31-CE7327F7BC61 Q37944849-00C0E4C5-7FB5-45C1-949C-BC50C448EDD1 Q37956537-9C77AF2B-40EB-48D9-8102-5A1ABC461F12 Q37982207-964B8734-B500-400E-B79A-8261DC3CABBE Q38003574-D65512AD-E4BC-4934-BF59-35D208F40CE5 Q38045284-A79B02AE-5C16-4218-947E-DC5467AE868A Q38205298-9F904FB7-CB1C-426E-83D2-5D4402528A5F Q39088514-00EDB766-3BEC-472D-84DA-0739F0500525 Q39882079-8396DE94-C419-4D70-B11E-A413E2952A32 Q42875420-69942098-F37A-4C77-8871-FA57863C264F Q43940054-BA30D54C-B551-489B-8F6B-115E60AD17EF Q47144755-38B21645-FC28-4AD6-A9B2-0AB5E8323B95 Q50133565-885CD8EE-289A-45BB-8F0A-6AF8DD2EBEDE Q50443416-51B08990-383A-4FA3-90E8-B15C48BF3CDA Q53686521-F4EB8471-84E6-4A23-838E-8637633BAEF9 Q58007726-71AAEBE0-A411-4B47-B91D-8DBF48E819E4 Q58570613-96A32CC4-B84B-4822-AB19-43535FDFADEE

P2860

Cardiovascular drug therapy in the elderly: benefits and challenges.

http://www.wikidata.org/entity/Q37803337

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiovascular drug therapy in the elderly: benefits and challenges.

@en

Cardiovascular drug therapy in the elderly: benefits and challenges.

@nl

type

label

Cardiovascular drug therapy in the elderly: benefits and challenges.

@en

Cardiovascular drug therapy in the elderly: benefits and challenges.

@nl

prefLabel

Cardiovascular drug therapy in the elderly: benefits and challenges.

@en

Cardiovascular drug therapy in the elderly: benefits and challenges.

@nl

P1433

Q37803337-1DC3FAF5-E867-43DB-B5DB-C7463FF4D3BB

P1476

Q37803337-A66B6338-7639-4814-9F9C-984975F73E2B

P2093

Q37803337-0D6ED0B5-E4AC-45EF-B7FD-102D7662EF14

Q37803337-6E2937D6-9197-4831-94BE-41F88D2D049C

Q37803337-842DC4C5-715F-46EC-B92B-FDD144F90906

P2860

Q37803337-0A51E1BB-D16B-4129-913D-3AEC68C2FEC9

Q37803337-0F72ED15-2789-42C6-AAF4-1B1594FD925E

Q37803337-2B246389-A748-4691-B861-47C79E8712FB

Q37803337-30DA0C78-4718-4C5C-9247-65CF0C7FE84E

Q37803337-61E181CA-670B-43F7-912F-3B64265B366D

Q37803337-73C90ACB-53AA-4A27-9E1B-D3AA97E4821E

Q37803337-9B549651-2E7A-4F2A-B932-F31E6B47BFBF

Q37803337-ADC365A0-BDA8-4539-A512-5E74214D52CD

Q37803337-B219C977-78EE-4E5E-8178-B94CEE72A9F6

Q37803337-B2C1282C-D388-4C37-98C4-4E6F1F8EC915

P304

Q37803337-54378F75-6153-4471-A8F1-296D63034F8C

P31

Q37803337-37D81D82-AE4A-4D51-A1D3-1BF4DA7CC943

P356

Q37803337-C4D08761-E58E-490F-9E51-1CF2BAAAD67A

P407

Q37803337-43394900-9C0B-4FE0-A629-1C6C4EA5CC64

P433

Q37803337-A30C09B3-7222-4A7B-B644-522A779A89E4

P478

Q37803337-52F897E5-0959-4374-B734-12826A0459E0

P577

Q37803337-1B6DC786-A18B-4242-AFD1-5738DAFCD654

P698

Q37803337-1C23E5EB-5A2F-4240-92CB-646653FC9BC8

P921

Q37803337-B78F5313-D80A-421F-A4CD-FDE079FEEB59

P356

NRCARDIO.2010.162

P1433

Nature Reviews Cardiology

P1476

Cardiovascular drug therapy in the elderly: benefits and challenges.

@en

P2093

Jerome L Fleg

http://www.w3.org/2001/XMLSchema#string

Wilbert S Aronow

http://www.w3.org/2001/XMLSchema#string

William H Frishman

http://www.w3.org/2001/XMLSchema#string

P2860

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.

Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand.

Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use.

Age as a determinant of sensitivity to warfarin.

Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group.

P304

13-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCARDIO.2010.162

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20978470

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio